

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056748 A1

(51) International Patent Classification⁷: **C07C 235/20**,
A61K 31/16

& D Sodertalje, S-151 85 Sodertalje (SE). **DAHLSTROM, Mikael, Ulf, Johan** [FI/SE]; AstraZeneca R & D Molndal, S-431 83 Molndal (SE).

(21) International Application Number:
PCT/GB2003/005602

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).

(22) International Filing Date:
19 December 2003 (19.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0229931.1 21 December 2002 (21.12.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except MG, US*): **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **LINDSTEDT ALSTERMARK, Eva-Lotte** [SE/SE]; AstraZeneca R & D Molndal, S-431 83 Molndal (SE). **OLSSON, Anna, Christina** [SE/SE]; AstraZeneca R & D Molndal, S-431 83 Molndal (SE). **LI, Lanna** [SE/SE]; AstraZeneca R & D Molndal, S-431 83 Molndal (SE). **AURELL, Carl-Johan** [SE/SE]; AstraZeneca R & D Sodertalje, S-151 85 Sodertalje (SE). **MINIDIS, Anna** [SE/SE]; AstraZeneca R & D Sodertalje, S-151 85 Sodertalje (SE). **YOUSEFI-SALAKDEH, Esmail** [IR/SE]; AstraZeneca R

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC AGENTS



(57) Abstract: The present invention provides the S enantiomer of a compound of formula (I) wherein R¹ represents chloro, trifluoromethyl or trifluoromethoxy, R² represents H or fluoro and R³ represents a C₂₋₄alkyl group as well as pharmaceutically acceptable salts, solvates and prodrugs thereof, to processes for preparing such compounds, to their utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

WO 2004/056748 A1